Subset of immune B cells delays onset of type 1 diabetes in animal model
Researchers at the Baylor College of Medicine and the University of Michigan Medical School have conducted a study showing that a specific subset of immune B cells delays the onset of type 1 diabetes in mice.
UGREEN 3S | Shutterstock
When the researchers transferred the immune cells, called CD19+IgM+ B cells, they found that the onset of the condition was delayed in an age-specific manner.
The finding, which has recently been described in the journal JCI Insight, could pave the way for the development of new therapies for type 1 diabetes.
"For many years, one of the research interests of my lab has been to better understand the role the immune system plays in type 1 diabetes,” said Pietropaolo.
A growing body of experimental evidence from studies of both animals and humans has pointed towards B cells as playing a key role in the development of diabetes. For example, research has shown that subsets of B cells can contribute directly to the development of the disease.
However, according to Pietropaolo, there are also indications that subsets of B cells may be involved in modulating the onset of the condition: "For instance, elimination of a specific subset of B cells carrying the μ-chain marker resulted in impaired diabetes progression in a mouse model."
In the current study, Pietropaolo and team found that transferral of CD19+ IgM+ B cells protected against diabetes onset in an age-specific manner, with diabetes onset being delayed in 6-week old mice, but not in mice that were older than 15 weeks.
.png)
No hay comentarios:
Publicar un comentario